Fernando Martinez, MD
Pulmonary Disease · Worcester, MANPI 1336221241
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Astrazeneca UK Limited at 26.2% of the total. Reporting peaked in 2019 at $102,685 and has fallen 68.8% since, to $32,039 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $1205.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$98K
- Boehringer Ingelheim International GmbH$86K
- GSK$70K
- AstraZeneca$34K
- Astrazeneca AB$28K
- CSL Behring$10K
- plus $49K from 15 others
Across 48 payments — averaging $796.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$17K
- Medtronic$9K
- Sanofi$6K
- Novartis$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Biogen$151
What the payments were for
- Consulting fees$152,63841%
- Speaking & faculty fees$39,95211%
- Travel & lodging$173,15846%
- Food & beverage$5,1711%
- Education$4,0691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 67 | $98,168 |
| Boehringer Ingelheim International GmbH | 68 | $85,985 |
| GSK | 45 | $69,640 |
| AstraZeneca | 45 | $34,467 |
| Astrazeneca AB | 29 | $28,002 |
| CSL Behring | 10 | $9,909 |
| Regeneron | 8 | $7,314 |
| Teva Pharmaceuticals USA, Inc. | 4 | $6,899 |
| Sanofi-aventis U.S. LLC | 4 | $5,838 |
| Chiesi USA, Inc. | 7 | $5,200 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $5,000 |
| United Therapeutics Corporation | 1 | $4,038 |
| Novartis | 1 | $3,195 |
| Sanofi | 2 | $2,729 |
| Boehringer Ingelheim | 4 | $2,216 |
| Zambon USA Ltd. | 7 | $2,169 |
| Sanofi US Services Inc. | 1 | $1,773 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,270 |
| Shionogi Inc | 1 | $1,110 |
| Zimmer Biomet | 1 | $51 |
| Roche Products Limited | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$70,629
- BEVESPI AEROSPHERE$22,546
- FASENRA$8,111
- DUPIXENT$7,242
- Zemaira$7,137
- BREZTRI$5,973
- TRELEGY ELLIPTA$5,850
- BREZTRI AEROSPHERE$5,499
- NUCALA$3,250
- AirDuo Digihaler$1,659
- ProAir Digihaler$1,659
- ArmonAir Digihaler$1,659
- STIOLTO RESPIMAT$1,600
- STIOLTO$564
How this compares
$374,988 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,435 |
| Prednisone | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat | $2,216 | $11,43516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Worcester
- Yaron GoldmanWorcester$843K
- Abdo KatayaWorcester$16K
- Sandeep SomalarajuWorcester$15K
- Kevin MartinWorcester$14K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.